India Court Upholds Higher Patent Standard for Drugs
By Mari Serebrov
Tuesday, April 2, 2013
Recognizing the global impact its decision could have, the Supreme Court of India denied an appeal by Novartis AG, ending the company's 15-year quest for a patent for its cancer drug Gleevec/Glivec.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.